Bionow Oncology Conference

Laura Rosenberg is the Director of Target Validation within Discovery Sciences at AstraZeneca Cambridge. A cell biologist by training, Laura has over 12 years' experience leading cross-discipline teams focused on the translation of novel and complex biology into drug discovery impact. Since 2021, her group at Astrazeneca has focused on the delivery of novel oncology targets to the pipeline driven by the belief that an enhanced understanding of disease/disease mechanism is required for effective drug discovery and to enhance chance of clinical success.

During her time at AZ, Laura has contributed to shaping the Functional Genomics strategy, utilizing this approach to drive deeper understanding of drug response, guide patient selection, inform rationale combinations and identify strategies to overcome resistance. Prior to joining AstraZeneca, Laura led a bioscience team at Cancer Research Horizons where she played a pivotal role in the establishment of industry partnered alliances. Here she worked closely with the CRUK academic network to deliver and progress numerous target opportunities, leading both bioscience and multi-disciplinary projects teams from concept to candidate.

Laura is a member of the ELRIG General Committee, The Biochemical Society Awards Committee, a PhD supervisor (Univ. Cambridge) and currently sits on the SAB for Worldwide Cancer Research.